Samsung Bioepis said Tuesday that Janssen, a pharmaceutical company of Johnson & Johnson, dropped all patent suits regarding Renflexis (Ingredient: Infliximab) in the U.S.
Renflexis, a biosimilar of Janssen’s Remicade, treats Crohn’s disease, adult ulcerative colitis, ankylosing spondylitis, adult plaque psoriasis, psoriatic arthritis, and rheumatic arthritis.
Janssen had initially filed a lawsuit against Samsung Bioepis for infringing on three of its patents regarding Remicade in May.
At the time of the lawsuit, Samsung Bioepis 삼성바이오에피스 believed that Renflexis did not infringe on any of Janssen’s patents. After judging that the lawsuit was a strategy to delay the biosimilar from entering the U.S. market, the company launched Renflexis in July.
Merck Sharp & Dohme (MSD) is in charge of Renflexis sales in the U.S. and Canada. The company plans to speed up the marketing of the drug after Janssen dropped its lawsuit.
<© Korea Biomedical Review, All rights reserved.>